beraprost 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
prostaglandins 343 88430-50-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • procylin
  • beraprost sodium
  • beraprost
stable prostacyclin analog; structure given in first source
  • Molecular weight: 398.50
  • Formula: C24H30O5
  • CLOGP: 1.89
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 3
  • TPSA: 86.99
  • ALOGS: -4.60
  • ROTB: 9

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 19 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.01 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1992 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiac failure 120.30 29.29 66 2942 89076 63396938
Pulmonary hypertension 116.16 29.29 49 2959 37074 63448940
Concomitant disease aggravated 106.38 29.29 32 2976 9080 63476934
Right ventricular failure 101.42 29.29 36 2972 17152 63468862
Transfusion 78.99 29.29 29 2979 15188 63470826
Brain natriuretic peptide increased 77.09 29.29 22 2986 5191 63480823
Hepatic function abnormal 71.60 29.29 35 2973 37107 63448907
Anaemia 67.65 29.29 76 2932 293354 63192660
Upper respiratory tract inflammation 67.44 29.29 17 2991 2506 63483508
Iron deficiency anaemia 57.90 29.29 25 2983 19944 63466070
Platelet count decreased 53.23 29.29 44 2964 116078 63369936
Pulmonary arterial hypertension 51.81 29.29 24 2984 22553 63463461
Gamma-glutamyltransferase increased 50.81 29.29 27 2981 34004 63452010
Blood pressure decreased 46.12 29.29 32 2976 64990 63421024
Pulmonary arterial pressure increased 35.04 29.29 11 2997 3584 63482430
Aspartate aminotransferase increased 34.80 29.29 31 2977 90246 63395768
Haematocrit decreased 34.24 29.29 22 2986 39318 63446696
Red blood cell count decreased 33.58 29.29 22 2986 40623 63445391
Renal impairment 33.38 29.29 30 2978 88325 63397689
Interstitial lung disease 31.59 29.29 25 2983 61883 63424131
Haemoglobin decreased 30.54 29.29 36 2972 145449 63340565

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Right ventricular failure 97.73 29.67 28 1250 8756 34946897
Concomitant disease aggravated 76.25 29.67 21 1257 5680 34949973
Cardiac failure 58.26 29.67 38 1240 91210 34864443
Brain natriuretic peptide increased 53.88 29.67 16 1262 5643 34950010
Pulmonary hypertension 52.84 29.67 22 1256 20902 34934751
Pulmonary arterial hypertension 35.56 29.67 13 1265 8726 34946927

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Right ventricular failure 184.99 27.10 64 4500 23433 79716391
Concomitant disease aggravated 173.47 27.10 53 4511 13114 79726710
Pulmonary hypertension 159.79 27.10 70 4494 48010 79691814
Cardiac failure 152.12 27.10 100 4464 154742 79585082
Brain natriuretic peptide increased 126.53 27.10 38 4526 8862 79730962
Hepatic function abnormal 83.47 27.10 52 4512 73055 79666769
Transfusion 80.45 27.10 34 4530 21296 79718528
Upper respiratory tract inflammation 78.53 27.10 22 4542 4013 79735811
Pulmonary arterial hypertension 77.32 27.10 36 4528 28330 79711494
Anaemia 74.25 27.10 108 4456 444907 79294917
Iron deficiency anaemia 65.09 27.10 31 4533 25641 79714183
Platelet count decreased 59.34 27.10 64 4500 194600 79545224
Gamma-glutamyltransferase increased 45.62 27.10 32 4532 54648 79685176
Blood pressure decreased 41.87 27.10 39 4525 99427 79640397
Aspartate aminotransferase increased 41.18 27.10 45 4519 138596 79601228
Interstitial lung disease 37.78 27.10 39 4525 112561 79627263
Pulmonary arterial pressure increased 34.23 27.10 12 4552 4543 79735281
Alanine aminotransferase increased 33.80 27.10 44 4520 162526 79577298
Fatigue 32.25 27.10 7 4557 929720 78810104
Haemoglobin decreased 31.34 27.10 50 4514 222069 79517755
Red blood cell count decreased 31.08 27.10 26 4538 57487 79682337
Blood urea increased 28.34 27.10 23 4541 48767 79691057
Haematocrit decreased 27.65 27.10 25 4539 61287 79678537
Renal impairment 27.19 27.10 39 4525 157744 79582080

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B01AC19 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Platelet aggregation inhibitors excl. heparin
MeSH PA D002317 Cardiovascular Agents
MeSH PA D006401 Hematologic Agents
MeSH PA D010975 Platelet Aggregation Inhibitors
MeSH PA D014665 Vasodilator Agents
CHEBI has role CHEBI:35620 vasodilator agents
CHEBI has role CHEBI:35674 antihypertensive drugs
CHEBI has role CHEBI:50427 platelet aggregation inhibitors
CHEBI has role CHEBI:66900 prostaglandin receptor agonists
CHEBI has role CHEBI:67079 anti-inflammatory agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Pulmonary arterial hypertension indication 11399002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.76 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Prostacyclin receptor GPCR AGONIST IC50 8.37 WOMBAT-PK DRUG LABEL
Prostaglandin E2 receptor EP3 subtype GPCR AGONIST Ki 6.17 IUPHAR
Prostaglandin E2 receptor EP4 subtype GPCR AGONIST Ki 5.14 IUPHAR
Prostacyclin receptor GPCR AGONIST Ki 7.80 IUPHAR
Prostacyclin receptor GPCR AGONIST Ki 7.72 IUPHAR

External reference:

IDSource
D01551 KEGG_DRUG
88475-69-8 SECONDARY_CAS_RN
C0053336 UMLSCUI
CHEBI:135633 CHEBI
CHEMBL1207745 ChEMBL_ID
CHEMBL435883 ChEMBL_ID
DB05229 DRUGBANK_ID
C048081 MESH_SUPPLEMENTAL_RECORD_UI
6917951 PUBCHEM_CID
1967 IUPHAR_LIGAND_ID
6261 INN_ID
35E3NJJ4O6 UNII
010867 NDDF
010868 NDDF

Pharmaceutical products:

None